Table 4.
Subgroup analysis of GPS and the risk of death in patients with NSCLC after stratified by potential confounders
| N | GPS 0 | GPS 1 | GPS 2 | P for trend | P interaction | |
|---|---|---|---|---|---|---|
| HR (95%CI) | HR (95%CI) | |||||
| Sex | 0.017 | |||||
| male | 328 | 1 | 1.61 (1.15, 2.25) | 2.65 (1.86, 3.78) | <0.0001 | |
| female | 166 | 1 | 1.01 (0.65, 1.59) | 1.26 (0.78, 2.05) | 0.3984 | |
| Age (years) | 0.802 | |||||
| <60 | 266 | 1 | 1.34 (0.94, 1.90) | 2.07 (1.38, 3.11) | 0.0006 | |
| ≥60 | 228 | 1 | 1.52 (1.02, 2.28) | 2.04 (1.37, 3.04) | 0.0005 | |
| Smoking history | 0.4351 | |||||
| never | 250 | 1 | 1.42 (1.00, 2.03) | 1.85 (1.23, 2.78) | 0.0023 | |
| ever | 242 | 1 | 1.42 (0.95, 2.11) | 2.33 (1.56, 3.48) | <0.0001 | |
| ECOG PSa | 0.7226 | |||||
| 0-1 | 414 | 1 | 1.39 (1.04, 1.86) | 2.10 (1.53, 2.89) | <0.0001 | |
| ≥2 | 53 | 1 | 1.79 (0.75, 4.28) | 2.10 (0.92, 4.80) | 0.082 | |
| Pathology | 0.729 | |||||
| Adenocarcinoma | 369 | 1 | 1.35 (1.00, 1.82) | 1.83 (1.31, 2.56) | 0.0004 | |
| SCCb | 109 | 1 | 1.63 (0.88, 3.00) | 2.84 (1.54, 5.24) | 0.0008 | |
| others | 16 | 1 | 4.37 (0.71, 26.81 | 4.20 (0.69, 25.49 | 0.1145 | |
| EGFR mutationc | 0.0649 | |||||
| negative | 141 | 1 | 2.30 (1.30, 4.07) | 1.97 (1.07, 3.61) | 0.0311 | |
| positive | 102 | 1 | 1.45 (0.76, 2.77) | 1.89 (0.93, 3.86) | 0.0681 | |
| unknown | 251 | 1 | 1.13 (0.80, 1.61) | 2.30 (1.60, 3.30) | <0.0001 | |
| Liver metastasis | 0.208 | |||||
| No | 419 | 1 | 1.46 (1.09, 1.95) | 2.03 (1.49, 2.76) | <0.0001 | |
| Yes | 64 | 1 | 1.08 (0.51, 2.29) | 3.00 (1.44, 6.24) | 0.0062 | |
| Sum of metastatic organs | 0.8993 | |||||
| 1-2 | 267 | 1 | 1.46 (1.02, 2.10) | 2.23 (1.51, 3.30) | <0.0001 | |
| ≥3 | 216 | 1 | 1.28 (0.85, 1.92) | 1.95 (1.29, 2.96) | 0.0017 | |
| TNM staged | 0.2811 | |||||
| IIIB | 75 | 1 | 1.65 (0.86, 3.18) | 1.27 (0.57, 2.86) | 0.3646 | |
| IV | 419 | 1 | 1.38 (1.04, 1.85) | 2.22 (1.65, 3.00) | <0.0001 | |
| Lactic dehydrogenase (U/L) | 0.1996 | |||||
| <285 | 358 | 1 | 1.44 (1.07, 1.95) | 1.81 (1.27, 2.57) | 0.0005 | |
| ≥285 | 136 | 1 | 1.33 (0.76, 2.34) | 2.55 (1.51, 4.33) | 0.0003 | |
| White blood cell (109/L) | 0.9672 | |||||
| <10 | 374 | 1 | 1.40 (1.05, 1.88) | 2.19 (1.56, 3.07) | <0.0001 | |
| ≥10 | 113 | 1 | 1.51 (0.66, 3.45) | 1.90 (0.85, 4.25) | 0.0964 | |
| D-dimer (mg/L) | 0.4186 | |||||
| <0.5 | 134 | 1 | 1.09 (0.66, 1.81) | 1.91 (0.99, 3.70) | 0.106 | |
| ≥0.5 | 317 | 1 | 1.64 (1.16, 2.33) | 2.07 (1.45, 2.95) | <0.0001 | |
| First-line treatment | 0.5202 | |||||
| chemotherapy | 243 | 1 | 1.55 (1.07, 2.24) | 2.79 (1.86, 4.19) | <0.0001 | |
| targeted therapy | 111 | 1 | 2.14 (1.18, 3.88) | 2.03 (1.02, 4.01) | 0.0157 | |
| combination therapy | 39 | 1 | 1.94 (0.56, 6.77) | 3.70 (0.94, 14.54) | 0.0597 | |
| Treatment Lines | 0.4744 | |||||
| <2 | 199 | 1 | 1.40 (0.93, 2.11) | 2.14 (1.39, 3.29) | 0.0007 | |
| ≥2 | 203 | 1 | 2.13 (1.36, 3.36) | 3.43 (2.04, 5.76) | <0.0001 |
Abbreviations: aEastern Cooperative Oncology Group performance status; bSquamous cell carcinoma; cEpidermal Growth Factor Receptor mutation; dTumor Node Metastasis stage.